Moreover, aberrant EGFR signalling, activated via mutation and amplification of EGFR, or phosphorylation of EGFR tyrosine kinase, is increasingly recognised as a driver of resistance to therapies in tumours [79,80,81]. Here, EGFR is linked to neoplasm.